SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT

被引：0
|
作者：
Van Cutsem, E. [1 ]
Berry, S. [2 ]
Michael, M. [3 ]
Kretzschmar, A. [4 ]
Rivera, F. [5 ]
DiBartolomeo, M. [6 ]
Mazier, M. [7 ]
Andre, N.
Cunningham, D. [8 ]
机构：
[1] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic, Australia
[4] Charite Campus Buch, Berlin, Germany
[5] Hosp M Valdecilla, Santander, Spain
[6] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[7] PARAXEL Int, Biostat & Programming, Paris, France
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [21] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [22] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [23] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [24] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [25] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
  • [26] Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
    Cassidy, J.
    Cunningham, D.
    Berry, S. R.
    Rivera, F.
    Clarke, S. J.
    Kretzschmar, A.
    Diaz-Rubio, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date
    Zhang, Guoliang
    Zhou, Xile
    Lin, Caizhao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 1434 - 1445
  • [28] Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer
    Sledge, G.
    Miller, K.
    Moisa, C.
    Gradishar, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [30] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345